MENU
ACLX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Arcellx (ACLX) Ownership - Who owns Arcellx?

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases... Show more

Profile

Industry
N/A
Address
800 Bridge Parkway
Phone
+1 240 327-0603
Employees
130
Web
https://www.arcellx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
3.82B
P/E Ratio
N/A
Total Cash
461.38M
Projected Growth
N/A
Total Debt
51.79M
Revenue
35.9M
Risk (Beta)
0.69
Dividend Yield
N/A
Total Cash/Share
7.98
Total Debt/Equity
N/A
Revenue/Share
0.65 USD as % of share price

Fundamentals

ACLX
Capitalization
3.82B
P/E Ratio
N/A
Risk (Beta)
0.69
Dividend Yield
N/A
Total Cash
461M
Total Cash/Share
7.98
Total Debt
51.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.65%
Revenue
35.9M
ROE
N/A
Book Value
441M
P/B Ratio
8.66
Cash Flow
N/A
Earnings
-3.93
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
56K
Current Ratio
3.99
Current Revenue Per Employee
30361.96
Dividends Per Share - Security
N/A
EBITDA
-209.52M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-30.67
Shares Held By Institutions
7.2B
Shares Outstanding - Current
57.8M
Total Liabilities
215M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-13.939
View a ticker or compare two or three
ACLX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACLX showed earnings on November 05, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
800 Bridge Parkway
Phone
+1 240 327-0603
Employees
130
Web
https://www.arcellx.com